MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

JNJ · NYSE

Johnson & Johnson

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$266.73As of Jul 28, 2026
Market capitalization$643B
52-week range$164.23–$269.43
S&P 500 portfolio weight1.00%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$255.00-4.4% vs. reference
Average$279.19+4.7% vs. reference
High$305.00+14.3% vs. reference
13 Buy4 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportNot availableSep 2026
Consensus EPS$3.046 estimates
Expected range$2.94–$3.14Low to high EPS
Dec 2026$11.68Street EPS consensus
Dec 2027$12.80Street EPS consensus
Dec 2028$14.27Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 28, 2025.

MetricCurrentPrior
Revenue+6.0% YoY$94.19B$88.82B
Operating income$25.29B$20.8B
Net income$26.8B$14.07B
Operating cash flow$24.53B$24.27B
Capital expenditures($4.83B)($4.42B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

These 3 Companies Reported Record Results and Raised Guidance

Zacks

Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?

RTTNews

Kymera Appoints Rooney As CMO Following Gollob's Retirement

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.